Evidence map›Paper›PMID 36268179›Full record

ArticleOncoimmunology2022

Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.

Xiaohuan Tang, Mengyuan Li, Xiaolong Wu, Ting Guo, Li Zhang, Lei Tang, Fangzhou Jia, Ying Hu, Yan Zhang, Xiaofang Xing and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Xiaohuan TangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Mengyuan LiDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, P.R. China.
Xiaolong WuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Ting GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Li ZhangDepartment of Pathology, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Lei TangDepartment of Radiology, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Fangzhou JiaBiological Sample Bank, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Ying HuBiological Sample Bank, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Yan ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Xiaofang XingKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Fei ShanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Xiangyu GaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Ziyu LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Cancer Center, Ward I, Peking University Cancer Hospital & Institute, Beijing, P.R. China.ORCID 0000-0001-5580-4979
Peking University · CN

Funding

Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemotherR01CA158202 · NCI · AUGUSTA UNIVERSITY · PI ZHOU, GANG · 2012 to 2016
$1.4M
NCI NIH HHS R01 CA158202
6 · The paper itself

Abstract

First-line PD-1 blockade plus chemotherapy significantly improves the survival benefits in late-stage gastric cancer (GC) patients. However, the pathological response rate and effects on the immune microenvironment of neoadjuvant PD-1 blockade plus chemotherapy in patients with cTNM-stage III GC remain to be elucidated. Patients with cTNM-stage III GC who underwent neoadjuvant PD-1 blockade plus chemotherapy and surgery were enrolled. Four

Indexed as

Neoadjuvant TherapyProgrammed Cell Death 1 ReceptorStomach NeoplasmsAnimalsMiceNeoplasm StagingTumor MicroenvironmentProgrammed Cell Death 1 ReceptorcTNM-stage III gastric cancerimmune cell subpopulationsneoadjuvant PD-1 blockade plus chemotherapypathological complete responsetumor microenvironment

Identifiers

PMID36268179
PMCPMC9578498
OpenAlexW4306318226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.